Apr 14, 2020
Eli Lilly has announced to begin clinical trials of rheumatoid arthritis drug Olumiant to treat COVID-19 patients. The company plans to explore the anti-inflammatory responses that were witnessed in rheumatoid arthritis patients, and how the drug – Olumiant – an oral JAK1/JAK2 inhibitor – might help in cur...
Read More...
Apr 02, 2020
Niacin might help in combating Glioblastoma Glioblastomas are difficult to treat in part as the brain’s immune cells are stifled and unable to attack against tumors. A research team of the University of Calgary in Canada revealed that a common vitamin might help resolve the issue. The researchers presen...
Read More...
Mar 26, 2020
FDA permits COVID-19 treatments with blood from survivors The FDA revealed the convalescent plasma use that is derived from the donated blood of people that have recovered from COVID-19 and that might have beneficial antibodies. It is being used as an investigational treatment for patients with severe cases of t...
Read More...
Mar 24, 2020
Thermo Fisher Scientific has announced to invest a hefty amount worth USD 800 Million across pharma manufacturing and services. The company plans to expand its capabilities in pharma manufacturing and services in the coming two years, with USD 475 Million reserved for 2020. The company has been acquirin...
Read More...
Mar 19, 2020
Sage Therapeutics seeking out to save flunked depression drug Sage Therapeutics has strategized on how to come back from the phase 3 failure of SAGE-217 in major depressive disorder. The plan focuses on three short-term studies Sage contemplates that may enable it to bring the GABA receptor positive allost...
Read More...
Mar 17, 2020
Moderna announces dozing of first patient with its mRNA1273 vaccine The pharmaceutical company, Moderna, has been developing a vaccine for the treatment of COVID-19. The vaccine is an mRNA-1273 is developed by scientist at NAID, in collaboration with Moderna, and the manufacturing of the vaccine for Phase I clin...
Read More...
Mar 12, 2020
The U.S. FDA has granted Janssen Pharmaceutical’s drug JNJ-6372, a Breakthrough Therapy designation for the treatment of metastatic non-small cell lung cancer (NSCLC) The drug has been recommended for its use in NSCLC patients with epidermal growth factor (EGFR) Exon 20 insertion mutations, categorized wit...
Read More...
Mar 11, 2020
Boehringer Ingelheim’s Ofev (nintedanib) has received FDA recommendation for the treatment of chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype Interstitial Lung Disease - ILD – a group of a large number of lung disorders resulting in scarring or fibrosis of lungs, caused by conditi...
Read More...
Mar 05, 2020
Killing brain tumors with the help of CAR-T CAR-T cell therapy is a technique which involves modifying patients' T cells to aim proteins associated with cancer that have revolutionized some of the blood cancers treatment. However, the technique has so far shown low potential in solid tumors like aggressive brain...
Read More...
Mar 03, 2020
Gilead Sciences has announced to purchase an Immuno-oncology company Forty Seven for USD 95.50 per share, totalling up to a deal value of USD 4.9 billion. By acquiring Forty Seven – named after its lead molecule - CD47 tumor cell protein - Gilead will acquire its lead candidate, Magrolimab, adding value to its ...
Read More...
Understanding Bone Densitometers: Technology, Applications, and Impact on Bone Health
Nov 04, 2025
Wireless Brain Sensors: Revolutionizing Neuroscience and Healthcare
Oct 28, 2025
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
Newsletter/Whitepaper